EMEA-001164-PIP01-11-M05
Key facts
| Invented name |
Veyvondi
|
| Active substance |
vonicog alfa
|
| Therapeutic area |
Haematology-Hemostaseology
|
| Decision number |
P/0494/2021
|
| PIP number |
EMEA-001164-PIP01-11-M05
|
| Pharmaceutical form(s) |
Powder and solvent for solution for injection
|
| Condition(s) / indication(s) |
Treatment of von Willebrand disease
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Baxalta Innovations GmbH
Tel. +800 6683 8470
|
| Decision type |
PM: decision on the application for modification of an agreed PIP
|